Results 91 to 100 of about 175,178 (288)

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

Advanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu, Chen Su, Jianling Liu, Mingyan Xing, Xiaoxia Wu, Lingxia Wang, Xiaoming Zhao, Hanwen Zhang, YangYang Xie, YangYang Wang, Hong Li, Yu Li, Ming Li, Haibing Zhang   +13 more
wiley   +1 more source

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Journal for ImmunoTherapy of Cancer, 2020
Background Tumor relapse due to mutation in CD19 can hinder the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Herein, we focused on lymphoma patients whose B cells exhibited a point mutation in CD19 of B cells after CAR-T cell infusion ...
Yi Zhang, Feng Li, Xinfeng Chen, Zhen Zhang, Yonggui Tian, Xuan Zhao, Jinyan Liu, Chang Yao   +7 more
doaj   +1 more source

Allogeneic Immune Cell Perfusion Inhibits the Growth of Vascularized 3D In Vitro Tumor Models, Induces Vascular Regression and Desmoplasia, but Promotes Tumor Cell Invasion

Advanced Science, EarlyView.
This study presents a vascularized 3D tumor model to investigate immune–stromal–tumor interactions under allogeneic PBMC perfusion. While immune cells induced tumor shrinkage, they also promoted vascular regression, stromal activation, and cancer cell invasion.
Alexandra Raab, Rasika Daware, Marcelo A. Szymanski de Toledo, Oskar Weber, Dimitris Kapsokalyvas, Twan Lammers, Horst Fischer, Federica De Lorenzi, Fabian Kiessling   +8 more
wiley   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

cDC1 Subtype‐Specific In Vivo Targeting of Liposomes

Advanced Science, EarlyView.
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf, Michael Fichter, Lin Jian, Felicia Schön, Carina Jung, Paul Schneider, Kai Speth, Ana Mateos‐Maroto, Volker Mailänder, Kaloian Koynov, Svenja Morsbach, Katharina Landfester   +11 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 as an Immune Marker in Tumor

International Journal of General Medicine
Lanyi Wei, Jingjing Meng, Danfeng Xiang, Quanjun Yang, Yangyun Zhou, Lingyan Xu, Junjun Chen,* Yonglong Han* Department of Pharmacy, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200030,
Wei L, Meng J, Xiang D, Yang Q, Zhou Y, Xu L, Chen J, Han Y   +7 more
doaj  

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Journal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang, Caili Zhang, Yingchun Zhang, Yuting Fan, Jing Zhang, Xiaojin Lin, Ting Guo, Yangzuo Gu, Jieheng Wu, Jianmei Gao, Xing Zhao, Zhixu He   +11 more
doaj   +1 more source

BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs

Advanced Science, EarlyView.
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, Mark E. Robinson, Kadriye N. Cosgun, Valeriya Malysheva, Ozgen Deniz, Nicholas T. Crump, Kaiyue Helian, Andrew J. Innes, Richard Burt, Li Sun, George John, Haibin Zhou, Atsunori Kaneshige, Longchuan Bai, Shaomeng Wang, Mikhail Spivakov, Markus Müschen, Niklas Feldhahn   +19 more
wiley   +1 more source